Early Stage

Developing treatments that change lives

Developing treatments that change lives


Raised to Date: Raised: $1,025,275

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common



SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Newport Beach, California

Business Type

High Growth

AiViva, with a valuation of $48.8 million, is raising funds on StartEngine. It is a biotechnology company that has created proprietary technology and new treatments in the fields of urology, oncology, dermatology, and ophthalmology. The JEL technology of AiViva enhances the benefits of drugs and prolongs their therapeutic effects, thus reducing the treatment frequency and improving outcomes. AiViva is conducting four clinical trials focused on wet AMD, non-melanoma skin cancer, and prostate disorders. Diane Tang-Liu founded AiViva in February 2020. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $5,000,000. The campaign proceeds will be used for research and development and the advancement of novel treatment paradigms.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 06/17/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Founder Profile

AiViva Founder Dr. Diane Tang-Liu on Advancing Medicine

It can be difficult and time-consuming to manage chronic and degenerative conditions. One example is wet age-related macular degeneration (AMD), a condition that causes abnormal blood vessel growth in the eye. These vessels leak fluid and scar the eye, affecting a person’s vision. The treatment for this condition is generally a monthly injection of eye medication.

AiViva has developed a treatment for this and other eye, skin, urinary tract, and cancer conditions that would provide more long-term relief. We spoke with AiViva founder and CEO Dr. Diane Tang-Liu about this new treatment and its potential applications.

Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.

Read Founder Interview

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
AiViva on StartEngine 2022
Platform: StartEngine
Security Type: Equity - Common
Valuation: $48,772,314
Price per Share: $2.00

Follow company

Follow AiViva on StartEngine 2022

Buy AiViva's Deal Report

Warning: according to the close date for this deal, AiViva may no longer be accepting investments.

AiViva Deal Report

Get KingsCrowd’s comprehensive report on AiViva including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether AiViva is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the AiViva deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge